{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/52063"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/52063","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"An extracellular vesicle therapeutic attenuates inflammation and damage in a Rhesus monkey model of cortical injury","abstract":"Cortical injury in the aged brain leads to acute cell death and inflammation, which trigger chronic secondary neurodegeneration resulting in long-term cognitive and motor deficits. There are no U.S. Food and Drug Administration (FDA)-approved therapeutics that address cortical injury pathologies. Recent studies in rodents and pigs have identified mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) as a promising therapeutic for cortical injury, reducing inflammation and enhancing neuroprotection. We have used MSC-EV treatment in a Rhesus monkey model of primary motor cortex injury which impairs fine motor function of the hand. When treated with MSC-EVs 24 hours and 2 weeks following injury, monkeys recovered pre-injury levels of function within the first 3-5 weeks post-injury, while untreated monkeys had an incomplete recovery. Analysis of brain tissue harvested 16 weeks post-injury found that MSC-EVs promoted homeostatic microglial phenotypes, neuronal plasticity, and myelin maintenance. These findings demonstrated the efficacy of MSC-EVs, but at which stage of recovery MSC-EVs acted remains unclear. Here, we assessed the progression of biomarkers of inflammation and damage across recovery and examined the brain at an earlier timepoint, 6-weeks post injury. The current study addresses the hypothesis that in the early stages of recovery, MSC-EVs attenuate the inflammatory response and reduce tissue damage. We first assessed how MSC-EVs affect the temporal progression of the inflammatory response, using a multiplex protein quantification platform (Olink) on plasma and cerebrospinal fluid (CSF) collected across recovery (pre-injury, 24 hours, 2-, 4-, and 6-weeks post-injury). MSC-EV treatment decreased inflammatory proteins in plasma 2 weeks following injury, with reductions in pro-inflammatory proteins persisting throughout recovery. Assessments of brain tissue revealed that at 6-weeks post-injury, MSC-EV treatment increased homeostatic microglial phenotypes, supporting an early shift towards an anti-inflammatory environment. Next, we assessed if MSC-EV treatment affected the progression, clearance and resolution of neurodegeneration across recovery. MSC-EV treatment was associated with increased levels of neurofilament-light (NF-L) chain, an axonal damage biomarker, in CSF after, coupled with increased neuronal structural integrity markers (MAP2) in brain tissue, suggesting an MSC-EV-mediated clearance of neuronal debris. MSC-EV treatment was also associated with a decrease in Galectin-3, presumably phagocytically active, microglia. Finally, to identify potential mechanisms of action, we performed lipidomic and metabolomic analyses of MSC-EV contents. We found sex-differences in MSC-EV cargo, female EVs were enriched in sugars, while male EVs were enriched in nitrogen-rich compounds. MSC-EVs cargo were related to cellular energy metabolism, supporting its potential role in metabolic efficiency in aging and after injury. Overall, these findings present a role of MSC-EVs in the early resolution of inflammation following cortical injury, creating a neuroprotective environment that supports recovery of motor function.","abstract_html":"Cortical injury in the aged brain leads to acute cell death and inflammation, which trigger chronic secondary neurodegeneration resulting in long-term cognitive and motor deficits. There are no U.S. Food and Drug Administration (FDA)-approved therapeutics that address cortical injury pathologies. Recent studies in rodents and pigs have identified mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) as a promising therapeutic for cortical injury, reducing inflammation and enhancing neuroprotection. We have used MSC-EV treatment in a Rhesus monkey model of primary motor cortex injury which impairs fine motor function of the hand. When treated with MSC-EVs 24 hours and 2 weeks following injury, monkeys recovered pre-injury levels of function within the first 3-5 weeks post-injury, while untreated monkeys had an incomplete recovery. Analysis of brain tissue harvested 16 weeks post-injury found that MSC-EVs promoted homeostatic microglial phenotypes, neuronal plasticity, and myelin maintenance. These findings demonstrated the efficacy of MSC-EVs, but at which stage of recovery MSC-EVs acted remains unclear. Here, we assessed the progression of biomarkers of inflammation and damage across recovery and examined the brain at an earlier timepoint, 6-weeks post injury. The current study addresses the hypothesis that in the early stages of recovery, MSC-EVs attenuate the inflammatory response and reduce tissue damage. We first assessed how MSC-EVs affect the temporal progression of the inflammatory response, using a multiplex protein quantification platform (Olink) on plasma and cerebrospinal fluid (CSF) collected across recovery (pre-injury, 24 hours, 2-, 4-, and 6-weeks post-injury). MSC-EV treatment decreased inflammatory proteins in plasma 2 weeks following injury, with reductions in pro-inflammatory proteins persisting throughout recovery. Assessments of brain tissue revealed that at 6-weeks post-injury, MSC-EV treatment increased homeostatic microglial phenotypes, supporting an early shift towards an anti-inflammatory environment. Next, we assessed if MSC-EV treatment affected the progression, clearance and resolution of neurodegeneration across recovery. MSC-EV treatment was associated with increased levels of neurofilament-light (NF-L) chain, an axonal damage biomarker, in CSF after, coupled with increased neuronal structural integrity markers (MAP2) in brain tissue, suggesting an MSC-EV-mediated clearance of neuronal debris. MSC-EV treatment was also associated with a decrease in Galectin-3, presumably phagocytically active, microglia. Finally, to identify potential mechanisms of action, we performed lipidomic and metabolomic analyses of MSC-EV contents. We found sex-differences in MSC-EV cargo, female EVs were enriched in sugars, while male EVs were enriched in nitrogen-rich compounds. MSC-EVs cargo were related to cellular energy metabolism, supporting its potential role in metabolic efficiency in aging and after injury. Overall, these findings present a role of MSC-EVs in the early resolution of inflammation following cortical injury, creating a neuroprotective environment that supports recovery of motor function.","abstract_has_math":false,"creators":["McCann, Ryan Patrick"],"institution":"Boston University","degree_name":"Doctor of Philosophy","degree_level":"doctoral","degree_discipline":"Neuroscience","degree_department":null,"school":null,"contributors":[],"advisors":["Moore, Tara L."],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-19T02:42:12Z","subjects":["Neurosciences","Biology","Extracellular vesicle","Inflammation","Mesenchymal","Microglia","Neuroprotection","Rhesus monkey"],"languages":["en_US"],"rights":["Attribution 4.0 International"],"rights_urls":["http://creativecommons.org/licenses/by/4.0/"],"identifier_entries":[],"person_identifier_entries":[{"key":"dc:identifier.orcid","label":"ORCID","values":["0000-0001-8498-9183"],"render_values":[{"text":"0000-0001-8498-9183","href":"https://orcid.org/0000-0001-8498-9183","code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2144/52063","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/52063","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F52063","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Moore, Tara L."]},{"key":"dc:creator","label":"Author","values":["McCann, Ryan Patrick"]},{"key":"dc:identifier.orcid","label":"ORCID","values":["0000-0001-8498-9183"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-01-23T20:35:08Z"]},{"key":"dc:date.embargo","label":"Dc Date Embargo","values":["2027-01-23T00:00:00Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2026-01-23T20:02:55Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Neuroscience"]},{"key":"thesis:degree_level","label":"Degree Level","values":["doctoral"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Neurosciences","Biology","Extracellular vesicle","Inflammation","Mesenchymal","Microglia","Neuroprotection","Rhesus monkey"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]},{"key":"dc:rights","label":"Dc Rights","values":["Attribution 4.0 International"]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://creativecommons.org/licenses/by/4.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/52063"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2026"]},{"key":"dc:description.abstract","label":"Abstract","values":["Cortical injury in the aged brain leads to acute cell death and inflammation, which trigger chronic secondary neurodegeneration resulting in long-term cognitive and motor deficits. There are no U.S. Food and Drug Administration (FDA)-approved therapeutics that address cortical injury pathologies. Recent studies in rodents and pigs have identified mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) as a promising therapeutic for cortical injury, reducing inflammation and enhancing neuroprotection. We have used MSC-EV treatment in a Rhesus monkey model of primary motor cortex injury which impairs fine motor function of the hand. When treated with MSC-EVs 24 hours and 2 weeks following injury, monkeys recovered pre-injury levels of function within the first 3-5 weeks post-injury, while untreated monkeys had an incomplete recovery. Analysis of brain tissue harvested 16 weeks post-injury found that MSC-EVs promoted homeostatic microglial phenotypes, neuronal plasticity, and myelin maintenance. These findings demonstrated the efficacy of MSC-EVs, but at which stage of recovery MSC-EVs acted remains unclear. Here, we assessed the progression of biomarkers of inflammation and damage across recovery and examined the brain at an earlier timepoint, 6-weeks post injury. The current study addresses the hypothesis that in the early stages of recovery, MSC-EVs attenuate the inflammatory response and reduce tissue damage. We first assessed how MSC-EVs affect the temporal progression of the inflammatory response, using a multiplex protein quantification platform (Olink) on plasma and cerebrospinal fluid (CSF) collected across recovery (pre-injury, 24 hours, 2-, 4-, and 6-weeks post-injury). MSC-EV treatment decreased inflammatory proteins in plasma 2 weeks following injury, with reductions in pro-inflammatory proteins persisting throughout recovery. Assessments of brain tissue revealed that at 6-weeks post-injury, MSC-EV treatment increased homeostatic microglial phenotypes, supporting an early shift towards an anti-inflammatory environment. Next, we assessed if MSC-EV treatment affected the progression, clearance and resolution of neurodegeneration across recovery. MSC-EV treatment was associated with increased levels of neurofilament-light (NF-L) chain, an axonal damage biomarker, in CSF after, coupled with increased neuronal structural integrity markers (MAP2) in brain tissue, suggesting an MSC-EV-mediated clearance of neuronal debris. MSC-EV treatment was also associated with a decrease in Galectin-3, presumably phagocytically active, microglia. Finally, to identify potential mechanisms of action, we performed lipidomic and metabolomic analyses of MSC-EV contents. We found sex-differences in MSC-EV cargo, female EVs were enriched in sugars, while male EVs were enriched in nitrogen-rich compounds. MSC-EVs cargo were related to cellular energy metabolism, supporting its potential role in metabolic efficiency in aging and after injury. Overall, these findings present a role of MSC-EVs in the early resolution of inflammation following cortical injury, creating a neuroprotective environment that supports recovery of motor function."]},{"key":"dc:title","label":"Title","values":["An extracellular vesicle therapeutic attenuates inflammation and damage in a Rhesus monkey model of cortical injury"]}]}],"canonical_facts":{"dc:contributor.advisor":["Moore, Tara L."],"dc:creator":["McCann, Ryan Patrick"],"dc:date.accessioned":["2026-01-23T20:35:08Z"],"dc:date.embargo":["2027-01-23T00:00:00Z"],"dc:date.issued":["2026"],"dc:date.updated":["2026-01-23T20:02:55Z"],"dc:description":["2026"],"dc:description.abstract":["Cortical injury in the aged brain leads to acute cell death and inflammation, which trigger chronic secondary neurodegeneration resulting in long-term cognitive and motor deficits. There are no U.S. Food and Drug Administration (FDA)-approved therapeutics that address cortical injury pathologies. Recent studies in rodents and pigs have identified mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) as a promising therapeutic for cortical injury, reducing inflammation and enhancing neuroprotection. We have used MSC-EV treatment in a Rhesus monkey model of primary motor cortex injury which impairs fine motor function of the hand. When treated with MSC-EVs 24 hours and 2 weeks following injury, monkeys recovered pre-injury levels of function within the first 3-5 weeks post-injury, while untreated monkeys had an incomplete recovery. Analysis of brain tissue harvested 16 weeks post-injury found that MSC-EVs promoted homeostatic microglial phenotypes, neuronal plasticity, and myelin maintenance. These findings demonstrated the efficacy of MSC-EVs, but at which stage of recovery MSC-EVs acted remains unclear. Here, we assessed the progression of biomarkers of inflammation and damage across recovery and examined the brain at an earlier timepoint, 6-weeks post injury. The current study addresses the hypothesis that in the early stages of recovery, MSC-EVs attenuate the inflammatory response and reduce tissue damage. We first assessed how MSC-EVs affect the temporal progression of the inflammatory response, using a multiplex protein quantification platform (Olink) on plasma and cerebrospinal fluid (CSF) collected across recovery (pre-injury, 24 hours, 2-, 4-, and 6-weeks post-injury). MSC-EV treatment decreased inflammatory proteins in plasma 2 weeks following injury, with reductions in pro-inflammatory proteins persisting throughout recovery. Assessments of brain tissue revealed that at 6-weeks post-injury, MSC-EV treatment increased homeostatic microglial phenotypes, supporting an early shift towards an anti-inflammatory environment. Next, we assessed if MSC-EV treatment affected the progression, clearance and resolution of neurodegeneration across recovery. MSC-EV treatment was associated with increased levels of neurofilament-light (NF-L) chain, an axonal damage biomarker, in CSF after, coupled with increased neuronal structural integrity markers (MAP2) in brain tissue, suggesting an MSC-EV-mediated clearance of neuronal debris. MSC-EV treatment was also associated with a decrease in Galectin-3, presumably phagocytically active, microglia. Finally, to identify potential mechanisms of action, we performed lipidomic and metabolomic analyses of MSC-EV contents. We found sex-differences in MSC-EV cargo, female EVs were enriched in sugars, while male EVs were enriched in nitrogen-rich compounds. MSC-EVs cargo were related to cellular energy metabolism, supporting its potential role in metabolic efficiency in aging and after injury. Overall, these findings present a role of MSC-EVs in the early resolution of inflammation following cortical injury, creating a neuroprotective environment that supports recovery of motor function."],"dc:identifier.orcid":["0000-0001-8498-9183"],"dc:identifier.uri":["https://hdl.handle.net/2144/52063"],"dc:language.iso":["en_US"],"dc:rights":["Attribution 4.0 International"],"dc:rights.uri":["http://creativecommons.org/licenses/by/4.0/"],"dc:subject":["Neurosciences","Biology","Extracellular vesicle","Inflammation","Mesenchymal","Microglia","Neuroprotection","Rhesus monkey"],"dc:title":["An extracellular vesicle therapeutic attenuates inflammation and damage in a Rhesus monkey model of cortical injury"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Neuroscience"],"thesis:degree_level":["doctoral"],"thesis:degree_name":["Doctor of Philosophy"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-19T02:42:12Z"}